Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
Cachexia is a clinical wasting syndrome that occurs in multiple disease states, and is associated with anorexia and a progressive loss of body fat and lean mass. The development of new therapeutics for this disorder is needed due to poor efficacy and multiple side effects of current therapies. The pivotal role played by the central melanocortin system in regulating body weight has made this an attractive target for novel cachexia therapies. The mixed melanocortin receptor antagonist AgRP is an endogenous peptide that induces hyperphagia. Here, we used AgRP(83-132) to investigate the ability of melanocortin antagonism to protect against clinical features of cachexia in two distinct animal models. In an acute model, food intake and body weight gain were reduced in mice exposed to radiation (300 RAD), and delivery of AgRP(83-132) into the lateral cerebral ventricle prevented these effects. In a chronic tumor cachexia model, adult mice were injected subcutaneously with a cell line derived from murine colon-26 adenocarcinoma. Typical of cachexia, tumor-bearing mice progressively reduced body weight and food intake, and gained significantly less muscle mass than controls. Administration of AgRP(83-132) into the lateral ventricles significantly increased body weight and food intake, and changes in muscle mass were similar to the tumor-free control mice. These findings support the idea that antagonism of the central melanocortin system can reduce the negative impact of cachexia and radiation therapy.
Joppa
M A
MA
Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA.
Gogas
K R
KR
Foster
A C
AC
Markison
S
S
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy; D054369:Agouti-Related Protein; D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000528:radiation effects; D002100:Cachexia / Q000209:etiology / Q000517:prevention & control*; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy; D004435:Eating / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010446:Peptide Fragments / Q000008:administration & dosage*; D011833:Radiation Injuries, Experimental / Q000517:prevention & control; D044101:Receptors, Melanocortin / Q000037:antagonists & inhibitors*
D054369:Agouti-Related Protein; D036341:Intercellular Signaling Peptides and Proteins; D010446:Peptide Fragments; D044101:Receptors, Melanocortin; C411703:agouti-related protein-(83-132)